The human immunodeficiency virus (HIV) epidemic remains a formidable global health
concern, with 39 million people living with the virus and 1.3 million new infections reported …

Encouraging results from preclinical and clinical studies support the development of bNAbs
for prevention and a number of antibodies with exceptional breadth and potency are …

Summary bNAbs may offer advantages over traditional ART for both the prevention and
treatment of HIV-1 infection. In addition, bNAbs may target the latent viral reservoir. bNAb …

Background: Although antiretroviral therapy (ART) effectively halts disease progression in
HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach
to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally …

In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several
HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles …

Broadly neutralizing antibodies for treatment and prevention... : Current Opinion in HIV and
AIDS Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection : Current …

Broadly neutralizing antibodies (bNAbs) have been evaluated as promising agents in the
fight against infectious diseases. HIV-1-specific bNAbs, in particular, have been tested in …

Early clinical studies support additional evaluation of bNAbs. Antibodies may offer
advantages over standard ART for HIV-1 prevention and therapy, and as components of …